Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors

Xiaoling Ding, Chen Zhu, Hui Qiang, Xiaorong Zhou, Guoxiong Zhou

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cyclooxygenase (COX)-2 and lipoxygenase (LOX)-5 are involved in carcinogenesis of pancreatic cancer. COX-2 inhibitor celecoxib displays inhibitory effects in pancreatic cancer cell growth. Recently, it has been reported that COX-2 inhibitor may not be able to suppress pancreatic tumor growth in vivo and its application is further limited by untoward side effects. The present study provides evidence that combined use of celecoxib and 5-LOX inhibitor MK886 markedly suppresses pancreatic tumor cell growth in vitro. Compared to the single inhibitor treatment, dual treatment with celecoxib and MK886 exerted additive antitumor effects in pancreatic tumor cells. We found that MK886 reversed celecoxib-induced increases in 5-LOX gene expression and Erk1/2 activation in pancreatic tumor cells. Moreover, Dual treatment of pancreatic tumor cells with celecoxib and MK886 inhibited the levels of LBT4 receptor BLT1 and vascular endothelial growth factor. Our results imply that combined use of celecoxib and MK886 might be an effective way to treat clinical patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)486-490
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume65
Issue number7
DOIs
StatePublished - Oct 2011

Fingerprint

Celecoxib
Lipoxygenase Inhibitors
Cyclooxygenase 2
Pancreatic Neoplasms
Arachidonate 5-Lipoxygenase
Cyclooxygenase 2 Inhibitors
Neoplasms
Growth
Vascular Endothelial Growth Factor Receptor
Carcinogenesis
Therapeutics

Keywords

  • Cyclooxygenase-2
  • Lipoxygenase-5
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology

Cite this

Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors. / Ding, Xiaoling; Zhu, Chen; Qiang, Hui; Zhou, Xiaorong; Zhou, Guoxiong.

In: Biomedicine and Pharmacotherapy, Vol. 65, No. 7, 10.2011, p. 486-490.

Research output: Contribution to journalArticle

Ding, Xiaoling ; Zhu, Chen ; Qiang, Hui ; Zhou, Xiaorong ; Zhou, Guoxiong. / Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors. In: Biomedicine and Pharmacotherapy. 2011 ; Vol. 65, No. 7. pp. 486-490.
@article{4d42fa7a637b4113a679534140295d96,
title = "Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors",
abstract = "Cyclooxygenase (COX)-2 and lipoxygenase (LOX)-5 are involved in carcinogenesis of pancreatic cancer. COX-2 inhibitor celecoxib displays inhibitory effects in pancreatic cancer cell growth. Recently, it has been reported that COX-2 inhibitor may not be able to suppress pancreatic tumor growth in vivo and its application is further limited by untoward side effects. The present study provides evidence that combined use of celecoxib and 5-LOX inhibitor MK886 markedly suppresses pancreatic tumor cell growth in vitro. Compared to the single inhibitor treatment, dual treatment with celecoxib and MK886 exerted additive antitumor effects in pancreatic tumor cells. We found that MK886 reversed celecoxib-induced increases in 5-LOX gene expression and Erk1/2 activation in pancreatic tumor cells. Moreover, Dual treatment of pancreatic tumor cells with celecoxib and MK886 inhibited the levels of LBT4 receptor BLT1 and vascular endothelial growth factor. Our results imply that combined use of celecoxib and MK886 might be an effective way to treat clinical patients with pancreatic cancer.",
keywords = "Cyclooxygenase-2, Lipoxygenase-5, Pancreatic cancer",
author = "Xiaoling Ding and Chen Zhu and Hui Qiang and Xiaorong Zhou and Guoxiong Zhou",
year = "2011",
month = "10",
doi = "10.1016/j.biopha.2011.06.009",
language = "English (US)",
volume = "65",
pages = "486--490",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "7",

}

TY - JOUR

T1 - Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors

AU - Ding, Xiaoling

AU - Zhu, Chen

AU - Qiang, Hui

AU - Zhou, Xiaorong

AU - Zhou, Guoxiong

PY - 2011/10

Y1 - 2011/10

N2 - Cyclooxygenase (COX)-2 and lipoxygenase (LOX)-5 are involved in carcinogenesis of pancreatic cancer. COX-2 inhibitor celecoxib displays inhibitory effects in pancreatic cancer cell growth. Recently, it has been reported that COX-2 inhibitor may not be able to suppress pancreatic tumor growth in vivo and its application is further limited by untoward side effects. The present study provides evidence that combined use of celecoxib and 5-LOX inhibitor MK886 markedly suppresses pancreatic tumor cell growth in vitro. Compared to the single inhibitor treatment, dual treatment with celecoxib and MK886 exerted additive antitumor effects in pancreatic tumor cells. We found that MK886 reversed celecoxib-induced increases in 5-LOX gene expression and Erk1/2 activation in pancreatic tumor cells. Moreover, Dual treatment of pancreatic tumor cells with celecoxib and MK886 inhibited the levels of LBT4 receptor BLT1 and vascular endothelial growth factor. Our results imply that combined use of celecoxib and MK886 might be an effective way to treat clinical patients with pancreatic cancer.

AB - Cyclooxygenase (COX)-2 and lipoxygenase (LOX)-5 are involved in carcinogenesis of pancreatic cancer. COX-2 inhibitor celecoxib displays inhibitory effects in pancreatic cancer cell growth. Recently, it has been reported that COX-2 inhibitor may not be able to suppress pancreatic tumor growth in vivo and its application is further limited by untoward side effects. The present study provides evidence that combined use of celecoxib and 5-LOX inhibitor MK886 markedly suppresses pancreatic tumor cell growth in vitro. Compared to the single inhibitor treatment, dual treatment with celecoxib and MK886 exerted additive antitumor effects in pancreatic tumor cells. We found that MK886 reversed celecoxib-induced increases in 5-LOX gene expression and Erk1/2 activation in pancreatic tumor cells. Moreover, Dual treatment of pancreatic tumor cells with celecoxib and MK886 inhibited the levels of LBT4 receptor BLT1 and vascular endothelial growth factor. Our results imply that combined use of celecoxib and MK886 might be an effective way to treat clinical patients with pancreatic cancer.

KW - Cyclooxygenase-2

KW - Lipoxygenase-5

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=80555131049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80555131049&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2011.06.009

DO - 10.1016/j.biopha.2011.06.009

M3 - Article

C2 - 21993002

AN - SCOPUS:80555131049

VL - 65

SP - 486

EP - 490

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 7

ER -